Pembrolizumab-Associated Hypoparathyroidism: A Single Case Report

Israa Mahmood1, Nitesh D Kuhadiya2, Michael Gonzalaes1

  • 1Division of Endocrinology, Diabetes and Metabolism, Renown Health, Reno, Nevada.

Summary

Pembrolizumab therapy can cause immune-mediated hypoparathyroidism, leading to hypocalcemia. Early recognition and treatment of this side effect are crucial for patient recovery.